KI and MSD in patient-centred research partnership

In November 2016, Karolinska Institutet entered a five-year research collaboration with pharmaceutical company MSD, a subsidiary of Merck and Co. Inc. The aim of the venture is to improve conditions for clinical research in the future and support product development by encouraging patient-centred studies – that is, studies on how approved drugs work in the real clinical world, a concept known as Real World Evidence.